BRM 2017 kicks-off on July 17 at the University of Toronto’s Rotman School of Management. Hosted by the Centre for Commercialization of Regenerative Medicine, a Toronto-based leader in developing and commercializing cell and gene therapies and regenerative medicine technologies, and the Rotman School, the three-day interactive event will generate discussions on the key issues on the business side of regenerative medicine industry.
The event runs from Monday, July 17 to Wednesday, July 19. It will be held at the Desautels Hall, Rotman School of Management, 105 St. George Street, Toronto.
The conference was originally conceived as a course taught at Case Western Reserve University in Cleveland, Ohio. It has since grown in scope and attendance to become a must-attend event for the regenerative medicine community.
Regenerative medicine harnesses the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs. It holds the promise of improving treatments for, and perhaps even curing, devastating and costly conditions such as diabetes, stroke and blindness. The current global market for regenerative medicine is US$36 billion and forecasted to reach $49.41 billion by 2021.
BRM 2017 will feature talks from Canadian and international experts, advice from seasoned entrepreneurs, panel discussions, pitches from start-ups and networking, with the aim of cultivating synergies, promoting learning and creating solutions to business challenges.
“Canada’s scientific output is on par with the world, but we are slow at turning discoveries into companies,” said Dr. Michael May, president and CEO of CCRM. “The more we invest in educating the community about how to commercialize RM technologies and therapies, the more patients will benefit from treatments – and possibly cures – and the Canadian economy will see a rise in high paying jobs.”
May said the regenerative medicine technologies, and cell and gene therapies are available to patients in the future, will depend on the research being conducted in labs today.
“Which ones succeed will depend on how research-oriented organizations and companies master critical business issues, including intellectual property, financing, regulatory, reimbursement and manufacturing,” he said. “By tackling these issues at BRM 2017, the industry will be well-equipped on the path to commercialization.”
“The Rotman School of Management understands the importance of integrating and applying best practices from the business world to the field of regenerative medicine, to help make this fledgling industry live up to its potential in the years to come,” said Will Mitchell, the Anthony S. Fell Chair in new technologies and commercialization, and professor of strategic management at the Rotman School.